Literature DB >> 12130697

Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition.

Phillip M Gerk1, Mary Vore.   

Abstract

The multidrug resistance protein 2 (MRP2; ABCC2) is an ATP-binding cassette transporter accepting a diverse range of substrates, including glutathione, glucuronide, and sulfate conjugates of many endo- and xenobiotics. MRP2 generally performs excretory or protective roles, and it is expressed on the apical domain of hepatocytes, enterocytes of the proximal small intestine, and proximal renal tubular cells, as well as in the brain and the placenta. MRP2 is regulated at several levels, including membrane retrieval and reinsertion, translation, and transcription. In addition to transport of conjugates, MRP2 transports cancer chemotherapeutics, uricosurics, antibiotics, leukotrienes, glutathione, toxins, and heavy metals. Several mutagenesis studies have described critical residues for substrate binding and various naturally occurring mutations that eliminate MRP2 expression or function. MRP2 is important clinically as it modulates the pharmacokinetics of many drugs, and its expression and activity are also altered by certain drugs and disease states.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130697     DOI: 10.1124/jpet.102.035014

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

1.  Immunocytochemistry for amoxicillin and its use for studying uptake of the drug in the intestine, liver, and kidney of rats.

Authors:  Kunio Fujiwara; Masashi Shin; Tsubasa Miyazaki; Yasuhiro Maruta
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

Review 2.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

Review 3.  Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Authors:  Kari T Kivistö; Mikko Niemi
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

4.  Myocardial ischaemia inhibits mitochondrial metabolism of 4-hydroxy-trans-2-nonenal.

Authors:  Bradford G Hill; Sunday O Awe; Elena Vladykovskaya; Yonis Ahmed; Si-Qi Liu; Aruni Bhatnagar; Sanjay Srivastava
Journal:  Biochem J       Date:  2009-01-15       Impact factor: 3.857

Review 5.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

6.  Cholesterol synthesis inhibition distal to squalene upregulates biliary phospholipid secretion and counteracts cholelithiasis in the genetically prone C57L/J mouse.

Authors:  G A Clarke; G Bouchard; B Paigen; M C Carey
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

Review 7.  Placental control of drug delivery.

Authors:  Sanaalarab Al-Enazy; Shariq Ali; Norah Albekairi; Marwa El-Tawil; Erik Rytting
Journal:  Adv Drug Deliv Rev       Date:  2016-08-12       Impact factor: 15.470

8.  Tobacco carcinogen NNK transporter MRP2 regulates CFTR function in lung epithelia: implications for lung cancer.

Authors:  Chunying Li; John D Schuetz; Anjaparavanda P Naren
Journal:  Cancer Lett       Date:  2010-01-20       Impact factor: 8.679

9.  Taurolithocholate-induced MRP2 retrieval involves MARCKS phosphorylation by protein kinase Cϵ in HUH-NTCP Cells.

Authors:  Christopher M Schonhoff; Cynthia R L Webster; M Sawkat Anwer
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

10.  Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.

Authors:  Kari T Kivistö; Jörg Zukunft; Ute Hofmann; Mikko Niemi; Sabine Rekersbrink; Swetlana Schneider; Gerd Luippold; Matthias Schwab; Michel Eichelbaum; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.